Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy

Br J Ophthalmol. 2007 Sep;91(9):1183-9. doi: 10.1136/bjo.2007.114769. Epub 2007 May 2.

Abstract

Aim: To evaluate expression of proangiogenic matrix metalloproteinases (MMP) 2 and 9 at distinct intervals after verteporfin photodynamic therapy (PDT) in human choroidal neovascular membranes (CNV) secondary to age-related macular degeneration (AMD).

Methods: Retrospective review of an interventional case series of 49 patients who underwent removal of CNV. Twenty-six patients were treated with PDT 3 to 383 days prior to surgery. Twenty-three CNV without previous treatment were used as controls. CNV were stained for CD34, cytokeratin 18, endostatin, MMP-2 and MMP-9 by immunohistochemistry.

Results: CNV without previous therapy disclosed MMP-2, MMP-9 in RPE-Bruch's membrane, vessels and stroma in different intensities. Three days after PDT, MMP-9 expression was significantly weaker in stroma (p = 0.0019). Endostatin was significantly reduced in vessels (p<0.001). At longer post-PDT intervals, a significant increase of MMP-9 in stroma (p = 0.037) and of endostatin in RPE-Bruch's membrane (p = 0.02), vessels (p = 0.005) and stroma (p<0.001) were disclosed. No significant changes in MMP-2 expression were detected.

Conclusions: PDT induced an early, temporary decrease in MMP-9 and endostatin expression. At longer intervals, MMP-9 increase is possibly associated with the angiogenic process responsible for recurrence after PDT. MMP-9, however, acts as a double-edged sword by concomitant induction of endostatin, an endogenous inhibitor of angiogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers / metabolism
  • Choroidal Neovascularization / enzymology*
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / surgery
  • Endostatins / metabolism
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Macular Degeneration / complications
  • Macular Degeneration / surgery
  • Male
  • Matrix Metalloproteinase 2 / metabolism*
  • Matrix Metalloproteinase 9 / metabolism*
  • Middle Aged
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use
  • Porphyrins / therapeutic use
  • Retrospective Studies
  • Verteporfin

Substances

  • Biomarkers
  • Endostatins
  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9